Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas

By L. Donehower, T. Soussi, Anil Korkut, Yuexin Liu, A. Schultz, Maria F. Cardenas, Xubin Li, O. Babur, Teng-Kuei Hsu, Olivier Lichtarge and 3 more. Cell Reports, 2019

554 citations recorded by the source corpus.

SUMMARY The TP53 tumor suppressor gene is frequently mutated in human cancers. Analysis of five data platforms in 10,225 patient samples from 32 cancers reported by The Cancer Genome Atlas (TCGA) has enabled comprehensive assessment of p53 pathway involvement in these cancers. Over 91% of TP53 mutant cancers exhibit second allele loss by mutation, chromosomal deletion, or copy neutral loss of heterozygosity. TP53 mutations are associated with enhanced chromosomal instability, including increased amplification of oncogenes and deep deletion of tumor suppressor genes. Tumors with TP53 mutations differ from their non-mutated counterparts in RNA, miRNA and protein expression patterns, with mutant TP53 tumors displaying enhanced expression of cell cycle progression genes and proteins. A mutant TP53 RNA expression signature showed significant correlation with reduced survival in 11 cancer types. Thus, TP53 mutation has profound effects on tumor cell genomic structure, expression, and clinical outlook.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/85c17bcf19d94eee4334f24d470237d8b757e795